新辅助化疗后根治性子宫颈切除术与直接腹式根治性子宫颈切除术治疗FIGO 2018 IB2期子宫颈癌的比较
本回顾性研究纳入51例FIGO 2018 IB2期子宫颈癌患者,16例选择新辅助化疗后根治性子宫颈切除术,35例选择直接腹式根治性子宫颈切除术。两组保留生育功能比例、并发症及5年无复发生存率均无显著差异,但新辅助化疗后肿瘤缩小<50%者复发率显著更高。
要点
- 新辅助化疗后根治性子宫颈切除术是部分IB2期患者可行的保留生育功能选择。
- 新辅助化疗组复发率相对较高但并发症较少,均无统计学显著性。
- 新辅助化疗后肿瘤缩小<50%是复发的唯一独立预测因素。
核心结论
- 新辅助化疗后根治性子宫颈切除术对于经过选择的IB2期子宫颈癌患者可能是可行的保留生育功能选择。
- 新辅助化疗组复发率相对较高且并发症较少,但无统计学显著性。
- 新辅助化疗后肿瘤退缩>50%的患者可能是新辅助化疗后行根治性子宫颈切除术的理想候选者。
研究设计与样本
- 回顾性研究,前瞻性收集2015年8月至2019年7月期间的数据。
- 共纳入51例希望保留生育功能的IB2期子宫颈癌患者,16例接受新辅助化疗后根治性子宫颈切除术,35例选择直接腹式根治性子宫颈切除术。
主要发现
- 新辅助化疗组和直接手术组分别有12例(75.0%)和27例(77.1%)患者保留了生育功能。
- 新辅助化疗组术中并发症发生率为0%,直接手术组为3.7%;术后并发症发生率分别为25.0%和48.1%(P=NS)。
- 新辅助化疗组11例(91.7%)和直接手术组17例(63.0%)患者术后接受了辅助化疗。
- 新辅助化疗组和直接手术组的中位随访时间分别为56个月和61个月,5年无复发生存率分别为83.3%和96.3%(P=NS)。
- 新辅助化疗后肿瘤缩小<50%的患者复发率高于肿瘤缩小>50%的患者(66.7% vs 0%,P<0.05)。
关键数值与推荐
- 新辅助化疗后肿瘤缩小<50%是接受新辅助化疗后根治性子宫颈切除术患者复发的唯一独立预测因素。
临床怎么用
- 作者认为新辅助化疗后根治性子宫颈切除术对于经过选择的IB2期子宫颈癌患者可能是可行的保留生育功能选择。
- 作者认为新辅助化疗后肿瘤退缩>50%的患者可能是新辅助化疗后行根治性子宫颈切除术的理想候选者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the optimal fertility-sparing treatment for stage IB2 cervical cancer. We compared the outcomes of neoadjuvant chemotherapy (NACT) followed by radical trachelectomy (RT) with those of upfront abdominal RT (ART). METHODS: This is a retrospective study with prospectively collected data between August 2015 and July 2019. Patients with IB2 cervical cancer who desired fertility preservation underwent NACT followed by RT, or upfront ART, per their choice. RESULTS: This study included 51 patients, of which, 16 patients underwent NACT followed by RT and 35 patients chose upfront ART. Fertility was preserved in 12 (75.0%) and 27 (77.1%) patients from the NACT and upfront ART groups, respectively. Incidence rates of intraoperative (0% versus 3.7%) and postoperative complications (25.0% versus 48.1%) of the NACT group were lower compared to the upfront ART group (P=NS). Eleven (91.7%) patients in NACT group and 17 (63.0%) patients in upfront ART groups received adjuvant chemotherapy after surgery. The median follow-up, and 5-year recurrence-free survival rates of the NACT-RT and upfront ART groups were 56 and 61 months, and 83.3% and 96.3%, respectively (P=NS). The recurrence rate was higher in patients with tumor reduction <50% after NACT than that in patients with tumor reduction >50% (66.7% versus 0%, P < 0.05). Tumor reduction <50% was the only independent predictor of recurrence in patients who underwent NACT before RT. CONCLUSIONS: NACT followed by RT could be a feasible fertility-sparing option for selected patients with 1B2 cervical cancer. The NACT group had a relatively higher recurrence rate and fewer complications compared to the upfront ART group, albeit without statistical significance. Patients with tumor regression >50% after NACT could be ideal candidates for RT after NACT.
引用
- Li X, Jiang Z, Lu J, et al. Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer. Gynecol Oncol. 2022. PMID: 36543029. doi:10.1016/j.ygyno.2022.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。